GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS (2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET
ANALYSIS (2020-2027)

• Global and China Osteoporosis Drugs Market, By
  Drug Type (Bisphosphonates (Alendronate,
  Risedronate, Ibandronate, Zoledronic Acid,
  Others), Calcitonin, Hormone Therapy, Selective
  Estrogen Receptor Modulators (SERMs), Parathyroid
  Hormone-Related Protein (PTHrP) Analog, Rank
  Ligand (RANKL) Inhibitor), By Route of
  Administration (Oral, Injectable, Others), By
  Distribution Channel (Hospitals Pharmacies,
  Online Pharmacies, Retail Pharmacies), and By
  Region (North America, Latin America, Europe,
  Asia Pacific, China, Middle East Africa) -
  Size, Share, Outlook, and Opportunity Analysis,
  2020 - 2027

3

• Osteoporosis is characterized by
  micro-architectural deterioration of bone tissue
  leading to low bone mass and bone fragility,
  especially in the older age. The condition
  affects both sexes however women are more prone
  to it, especially post-menopause when bone loss
  is accelerated due to reduced estrogen, which
  helps protect the bones.

4
Statistics

• The global and China osteoporosis drugs market is
  estimated to account for US 17.1 Bn in terms of
  value by the end of 2027.

5
Global and China Osteoporosis Drugs Market
Drivers

• Increasing prevalence of osteoporosis is expected
  to propel growth of the global and China
  osteoporosis drugs market over the forecast
  period. For instance, according to the study,
  The Prevalence of Osteoporosis in China, a
  Nationwide, Multicenter DXA Survey, published in
  October 2019, in The Journal of Bone and Mineral
  Research, the age-standardized prevalence of
  osteoporosis at the spine or hip was 6.46 and
  29.13 for men and women aged 50 years and older,
  respectively. A total of 10.9 million men and
  49.3 million women in China were estimated to
  have osteoporosis.
• Moreover, increasing geriatric population is also
  expected to aid in growth of the market. For
  instance, according to the United Nations,
  Department of Economic and Social Affairs,
  Population Division, the geriatric population in
  China is expected to reach 246,986 thousands in
  2030 from 164,487 thousands in 2019.

6
Statistics

• North America held dominant position in the
  global and China osteoporosis drugs market in
  2019, accounting for 38.5 share in terms of
  value, followed by Europe and Asia Pacific,
  respectively.

7
Figure 1 Global and China Osteoporosis Drugs
Market Share () Value, By Region, 2019
8
Global and China Osteoporosis Drugs Market
Restraints

• Adverse effects of osteoporosis drugs are
  expected to hinder growth of the market. For
  instance, consumption of alendronate may lead to
  stomach pain, acid reflux, constipation,
  diarrhea, upset stomach, nausea, or muscle and
  joint pain.
• Moreover, low awareness and diagnosis of
  osteoporosis, especially in emerging economies is
  also expected to limit the market growth.

9
(No Transcript)
10
Global and China Osteoporosis Drugs Market
Opportunities 

• RD in novel therapeutics is expected to offer
  lucrative growth opportunities for players in the
  global and China osteoporosis drugs market. For
  instance, in June 2020, researchers from School
  of Medicine CHA University, South Korea, reported
  that Tauroursodeoxycholic acid, the U.S.
  FDA-approved hydrophilic bile acid for the
  treatment of chronic cholestatic liver disease,
  may provide a favorable effect on bones and could
  be used for the prevention and treatment of
  osteoporosis.
• Moreover, increasing number of smokers is also
  expected to aid in growth of the market. For
  instance, according to the World Health
  Organization, 1.337 billion people smoked tobacco
  worldwide in 2018.

11
Statistics

• The global and China osteoporosis drugs market
  was valued at US 12.7 Bn in 2019 and is forecast
  to reach a value of US 17.1 Bn by 2027 at a CAGR
  of 3.8 between 2020 and 2027.

12

• Figure 2 Global and China Osteoporosis Drugs
  Market Value (US Bn), 2016 2027

13
Market Trends/Key Takeaways

• Major organizations are focused on reducing the
  burden of osteoporosis. For instance, in June
  2020, The International Osteoporosis Foundation
  partnered with Amgen and UCB, a global
  biopharmaceutical company, in collaboration with
  the University of Oxford, to support its Capture
  the Fracture program, which aims to reduce hip
  and vertebral fractures by 25 by 2025.

14

• Approval and launch of AI-based products to
  predict osteoporosis is expected to aid in growth
  of the market. For instance, in May 2020, Zebra
  Medical Vision received FDA 510(k) clearance for
  its Vertebral Compression Fractures product,
  which automatically identifies findings
  suggestive of compression fractures, which
  enables clinicians to place patients that are at
  risk of osteoporosis in treatment pathways.

15
Global and China Osteoporosis Drugs Market
Competitive Landscape

• Major players operating in the global and China
  osteoporosis drugs market include, Merck Co.,
  Eli Lilly, Procter Gamble, Enzo Biochem, Inc.,
  Sanofi-Aventis, Novartis, Wyeth, Roche,
  GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd.,
  Bone Biologics, Teijin Pharma Limited, JHL
  Biotech Inc., Keros Therapeutics, and Taro
  Pharmaceuticals Inc.

16
Global and China Osteoporosis Drugs Market Key
Developments

• Major players in the market are focused on
  approval and launch of new products to expand
  their product portfolio. For instance, in May
  2020, Teijin Pharma Limited, a partner of Radius
  Health, Inc., submitted a New Drug Application
  for abaloparatide-SC in Japan for the treatment
  of osteoporosis in patients who are at high risk
  for fractures.
• Similarly, in April 2019, Amgen and UCB received
  the U.S. Food and Drug Administration approval
  for EVENITY (romosozumab-aqqg) for the treatment
  of osteoporosis in postmenopausal women at high
  risk for fracture.

17

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  market-insight/global-and-china-osteoporosis-drugs
  -market-4018

18
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

19
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

20

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/